A 12-week, Double-blind, Randomized, Multi-centre, Parallel-group Study Evaluating the Efficacy Safety, and Patient Use (User Study) of Symbicort (Budesonide/Formoterol) Breath Actuated Metered Dose Inhaler (BA MDI) 2x160/4.5 µg Twice Daily Compared With Symbicort (Budesonide/Formoterol) AC (Actuation Counter) pMDI 2x160/4.5 µg Twice Daily and Budesonide AC pMDI 2x160 µg Twice Daily in Adult and Adolescent Asthmatics.
Phase of Trial: Phase III
Latest Information Update: 03 Jan 2015
At a glance
- Drugs Budesonide/formoterol (Primary) ; Budesonide
- Indications Asthma
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 04 Mar 2014 Primary endpoint 'Forced-expiratory-volume-in-1-second' has been met.
- 04 Mar 2014 Results presented at the 70th Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
- 01 Aug 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History